FALCONE, COLOMBA
 Distribuzione geografica
Continente #
NA - Nord America 6.626
EU - Europa 5.022
AS - Asia 3.481
OC - Oceania 12
AF - Africa 9
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.162
Nazione #
US - Stati Uniti d'America 6.557
CN - Cina 3.101
IE - Irlanda 1.469
UA - Ucraina 968
FI - Finlandia 715
DE - Germania 581
IT - Italia 461
SE - Svezia 367
SG - Singapore 309
GB - Regno Unito 223
FR - Francia 104
CA - Canada 67
BE - Belgio 51
IN - India 24
CZ - Repubblica Ceca 21
NL - Olanda 15
JP - Giappone 13
AU - Australia 11
RU - Federazione Russa 10
MU - Mauritius 8
HK - Hong Kong 7
IR - Iran 7
TR - Turchia 6
CL - Cile 4
ES - Italia 4
HU - Ungheria 4
LV - Lettonia 4
SA - Arabia Saudita 4
AR - Argentina 3
AT - Austria 3
EU - Europa 3
KR - Corea 3
RO - Romania 3
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
ID - Indonesia 2
IS - Islanda 2
MX - Messico 2
NO - Norvegia 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
Totale 15.162
Città #
Chandler 1.527
Dublin 1.468
Jacksonville 1.198
Nanjing 866
Boardman 454
Nanchang 355
Ashburn 343
Beijing 313
Princeton 279
Hebei 270
Shenyang 263
Lawrence 257
Ann Arbor 256
Medford 239
Changsha 234
Singapore 217
Helsinki 211
Jiaxing 194
Wilmington 192
Tianjin 158
Hangzhou 145
Shanghai 105
Milan 90
New York 90
Woodbridge 68
Seattle 62
Piscataway 58
Toronto 58
Brussels 51
Verona 48
Pavia 43
Norwalk 41
Los Angeles 37
Kunming 32
Des Moines 28
Dearborn 21
Fairfield 20
Falkenstein 16
Jinan 16
Brno 14
Ningbo 14
Zhengzhou 14
Dallas 13
Lanzhou 13
Munich 13
Berlin 12
Palermo 12
Pune 12
Auburn Hills 11
Houston 11
Tokyo 11
Guangzhou 10
London 10
Rome 10
San Francisco 10
Washington 10
Changchun 9
Frankfurt am Main 9
Tappahannock 9
Taizhou 8
Canberra 7
Meda 7
Borås 6
Fuzhou 6
Leawood 6
Olomouc 6
Bareggio 5
Brescia 5
Chicago 5
Gunzenhausen 5
Napoli 5
Ottawa 5
Falls Church 4
Naples 4
Orange 4
Redwood City 4
Riyadh 4
Trieste 4
Amsterdam 3
Andover 3
Bologna 3
Bra 3
Cive 3
Concepción 3
Hanover 3
Hefei 3
Latina 3
Melbourne 3
Sestri Levante 3
Sopron 3
Vienna 3
Zanjan 3
Agrigento 2
Atlanta 2
Bratislava 2
Buenos Aires 2
Busto Arsizio 2
Cambridge 2
Canyon Country 2
Castelnuovo Rangone 2
Totale 10.708
Nome #
Ruolo dell'infiammazione e della risposta immune nell'aterosclerosi: studio del polimorfismo Asp299Gly del gene TLR4 (Toll Like Receptor 4) in pazienti CAD. 144
Studio di genere: possibile ruolo del polimorfismo Val66Met del BDNF nella malattia coronarica e nella depressione. 140
Riscontro ecocardiografico di apposizioni trombotiche nei pazienti con fibrillazione atriale: predittività del punteggio CHADS2 in relazione alla strategia di prevenzione degli eventi tromboembolici 122
Beta-endorphins during coronary angioplasty in patients with silent or symptomatic myocardial ischemia 105
Studio del polimorfismo 14 bp inserzione/delezione nel gene HLA-G e insorgenza della CAD (Coronary Artery Disease) 102
Analisi molecolare e immunocitochimica dell'espressione del gene RAGE in pazienti CAD (Coronary Artery Disease). 99
Ruolo dei polimorfismi del gene TNF e dei suoi recettori (TNFR1 e TNFR2) nello sviluppo di aterosclerosi coronarica 97
Plasma eotaxin concentrations are associated with angiographic severity of coronary artery disease 96
Soluble RAGE Plasma Levels in Patients with Coronary Artery Disease and Peripheral Artery Disease 96
Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. 93
Age of Onset of Myocardial Infarction: Is Promoter Polymorphism of the RAGE Gene Implicated? 93
Infarto miocardico ed età di insorgenza: è implicato il polimorfismo -374T/A del gene RAGE nello studio di genere? 92
Mental stress as a provocative test in patients with various clinical syndromes of coronary heart disease. 89
Atrial fibrillation recurrence and expression levels of apelin-regulating miRNAs 89
Relationship between plasma levels of soluble receptor for advanced glycation end products (sRAGE) and coronary artery disease 88
-374 T/A, -429 C/T and G82S polymorphisms of the receptor for advanced glycation endproducts (RAGE) gene (HLA class III) and risk of coronary artery disease (CAD) in Caucasian Italian subjects. 87
CAD (Coronary Artery Disease) diabetes and HLA class III RAGE (Receptor for Advanced Glycation End products) gene polymorphisms. 86
Dental pain threshold and excercise-induced silent ischemia in hypertensive and normotensive patients 86
Significato prognostico dei livelli plasmatici di osteopontina in pazienti con angina pectoris stabile 86
Associazione tra il polimorfismo RAGE (Receptor for Advanced Glycation Endproducts) - 374 T/A e la presenza di diabete in soggetti CAD. 85
Diabetes mellitus and silent myocardial ischemia in patients with coronary artery disease: comparison between patients with and without simptoms during provocative test. 84
Peripheral benzodiazepine receptor (pBZR) expression on leucocytes in patients with ischemic heart disease 84
Relationship between apolipoprotein(a) size polimorphism and coronary heart disease in overweight subjects 83
RAGE : a central player in nondiabetic vascular disease 83
Correlation between mucosal levels of receptor for advanced glycation end products (RAGE) with inflammatory indexes in crohn's disease and ulcerative colitis 81
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men 80
Associazione tra la concentrazione plasmatica di eotaxina e coronaropatia in pazienti sottoposti ad angiografia coronarica 80
Does Nifedipine increased coronary flow during exercise in patients with exertional angina? 80
Thrombolisis versus PTCA in patients with recent myocardial infarction: exercise stress echocardiography study 79
Association between platelet endothelial cellular adhesion molecole 1 ( PECAM-1/CD31) polymorphisms and atherosclerosis: results of a study performed in patients from north Italy 78
La chemochina regolatoria eotaxina-3 quale nuovo fattore predittivo di outcome cardiovascolare in pazienti con angina pectoris stabile 78
Apo(a) isoforms: a genetic marker for progression of coronary atherosclerosis. 78
Effects of physical training on cardiovascular control after heart transplantation 78
-374T/A and -429 T/C polymorphisms of the RAGE gene in Myocardial Infarction. 77
Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion 77
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension 76
Therapeutic approach in patients with stable angina 76
Aterosclerosi e CAD (Coronary artery disease): analisi dei polimorfismi del recettore CR1 76
Approccio genetico-clinico alla cardiopatia ischemica: analisi di 14 casi familiari. 76
Improvement in exercise capacity, right heart hemodynamics and right ventricular function after pulmonary endarterectomy in patients with chronic thromoboembolic pulmonary hypertension. 75
Association between platelet endothelial cellular adhesion molecule-1 polymorphisms and atherosclerosis: results of a study on patients from northern Italy 75
Analysis of CR1 and CR2 polymorphisms in Italian patients with angiographically documented coronary artery disease (CAD). 75
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction 74
The regulatory chemokine eotaxin-3 is a novel predictor of cardiovascular outcome in patients with coronary artery disease 74
374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis 74
Ruolo prognostico del polimorfismo -374 T/A del gene RAGE (recettore per i prodotti finali di glicazione avanzata) nei pazienti con sospetta coronaropatia 74
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects 74
Cateterismo transettale con sistema a radiofrequenza: un nuovo approccio alternativo alla convenzionale puntura del setto con ago d’acciaio 73
Galectin-3 plasma levels andcoronary artery disease: a new possible biomarker of acute coronary syndrome. 73
Analisi mutazionale di Kir6.1/KCNJ8 in pazienti con angina vasospastica 73
Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT 72
Disfunzione erettile come predittore di eventi cardiovascolari maggiori in diabetici con coronaropatia silente angiograficamente documentata 71
Signal averaged elettrocardiography in patients with chronic ischemic heart disease. 71
CORRELAZIONE TRA I LIVELLI PLASMATICI DI NEUROTROFINE, SINTOMATOLOGIA DEPRESSIVA E ATEROSCLEROSI CORONARICA 71
Rapid heart rate increase at onset of exercise predicts adverse cardiac events in patients with coronary artery disease 70
Study of the espression of receptor for advanced glycation end products (RAGE), in inflammatory bowel disease 70
Effect of PTCA on hyperventilation induced vasomotor response in stable angina 70
Significance of the walk-through angina phenomenon during exercise testing 70
Circulating levels of osteopontin predicts future cardiac events in patients with chronic stable angina 69
Non-respiratory components of heart rate variability in heart transplant recipients: evidence of autonomic reinnervation? 69
Forma solubile del recettore dei prodotti finali di glicazione avanzata (sRAGE) ed aterosclerosi coronarica 69
A double comparison of Nicoradil and isosprbide dinitrate slow release in patients with stable angina pectoris 69
Factors moduleting respiratory sinus arrhytmia during physical exercise in heart transplanted patients 69
Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk 69
Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. 68
Relationship between the -374 T/A Rage polymorphism and severity of coronary atherosclerosis 68
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension 68
QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism 68
Role of TNF and its receptors (TNFR1, TNFR2) in Coronary Artery Disease (CAD). 67
POLIMORFISMO DEL GENE RAGE E MANIFESTAZIONI CLINICHE DELLA CARDIOPATIA ISCHEMICA 67
Role of the advanced glycation end products receptor in Crohn’s disease inflammation 67
Biomarcatori infiammatori e neuro-ormonali nella fibrillazione atriale persistente; ruolo prognostico della concentrazione plasmatica di apelina 66
Coronary artery disease and depression: possible role of brain-derived neurotrophic factor and serotonin transporter gene polymorphisms 66
Association between two polymorphisms in the HLA-G gene and angiographic coronaryartery disease 66
Gene RAGE e cardiopatia ischemica: ruolo del polimorfismo –374 T/A nell’estensione della coronaropatia 66
Peripheral benzodiazepine receptors expression on leucocytes in patients with ischemic heart disease 66
Transcutaneous Oxygen Tension as a Potential Predictor of Cardiovascular Events in Type 2 Diabetes: Comparison with ankle-brachial index 66
Polimorfismi del gene RAGE (Receptor for Advanced Glycation Endproducts) e CAD (Coronary Artery Disease): studio dell'implicazione nell'eterogeneità di malattia 65
Silent coronary artery disease in type 2 diabetes mellitus: the role of Lipoprotein(a), homocysteine and apo(a) polymorphism 65
Studio dei polimorfismi nel gene del recettore dell’apelina in pazienti con e senza ipertensione arteriosa 65
Correlazione tra normalizzazione emodinamica e recupero funzionale nei pazienti sottoposti a tromboendoarteriectomia polmonare per ipertensione polmonare cronica tromboembolica 65
Ormonoterapia e cardiopatia ischemica nella donna in menopausa. 65
Exercise stress echocardiography i patientswith and without angina during myocardial ischemia. 65
Increased expression of peripheral benzodiazepine receptors on leukocytes in silent myocardial ischemia 65
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans 64
Il six minute walking test è un indice attendibile nella valutazione del recupero funzionale nei pazienti con cuore polmonare cronico tromboembolico sottoposti ad endoarteriectomia polmonare 64
Coronary arterial spasm as a cause of exercise-induced ST-segment elevation in patients with variant angina 64
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease 64
Association between the -374 T/A polymorphism of RAGE gene and coronary artery disease 64
Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients 63
Angina at rest. Clinical, electrocardiographic and angiographic observations in 107 patients 63
Dental pain threshold and angina pectoris in patients with coronary artery disease 63
Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. 63
The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn’s Disease: A Cross-Sectional Study 63
A W148R mutation in the human FOXD4 gene segregating with dilated cardiomyopathy, obsessive-compulsive disorder, and suicidality 63
Associazione tra i polimorfismi della molecola di adesione PECAM-1/CD31 ed aterosclerosi: risultati di uno studio condotto in pazienti dell'Italia del nord. 62
Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target 62
The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. 62
CD14 polymorphisms and ACS (Acute Coronary Syndromes) 62
Age of onset of myocardial infarction: is promoter polymorphism of the RAGE gene implicated? 62
Totale 7.604
Categoria #
all - tutte 56.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.019


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.005 0 0 0 0 0 214 39 205 21 330 185 11
2020/20211.797 207 167 58 189 14 246 23 249 62 272 244 66
2021/20221.198 22 8 50 22 8 40 18 59 62 37 185 687
2022/20234.306 479 321 49 353 482 415 2 279 1.746 44 85 51
2023/20241.314 177 237 49 107 95 326 13 113 11 32 99 55
2024/2025834 77 295 152 98 58 154 0 0 0 0 0 0
Totale 15.237